DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

21 Drugs in Development

21 Drugs in Development

DIGITAL CONTENT

13 NEWS #PharmaBuzz

media
13 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

21DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Img-7289, Bomedemstat [usan], Y2t4aldeat, 1990504-34-1, Benzamide, n-((1s)-4-(((1r,2s)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1h-1,2,3-triazol-1-yl)-, Unii-y2t4aldeat

Molecular Formula

C₂₈H₃₄FN₇O₂

Molecular Weight

519.6 g/mol

InChI Key

KQKBMHGOHXOHTD-KKUQBAQOSA-N

FDA UNII

Y2T4ALDEAT

Bomedemstat is an orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, bomedemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; thus, inhibition of LSD1 also promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression, tumor cell growth and survival.

1 2D Structure

Bomedemstat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide

2.1.2 InChI

InChI=1S/C28H34FN7O2/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37)/t24-,25-,26+/m0/s1

2.1.3 InChI Key

KQKBMHGOHXOHTD-KKUQBAQOSA-N

2.1.4 Canonical SMILES

CN1CCN(CC1)C(=O)C(CCCNC2CC2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5

2.1.5 Isomeric SMILES

CN1CCN(CC1)C(=O)[C@H](CCCN[C@@H]2C[C@H]2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5

2.2 Other Identifiers

2.2.1 UNII

Y2T4ALDEAT

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Img-7289

2. Bomedemstat [usan]

3. Y2t4aldeat

4. 1990504-34-1

5. Benzamide, N-((1s)-4-(((1r,2s)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1h-1,2,3-triazol-1-yl)-

6. Unii-y2t4aldeat

7. Bomedemstat [inn]

8. Bomedemstat [who-dd]

9. Chembl4297289

10. Schembl17984236

11. Bdbm425083

12. Who 11114

13. Us10519118, Example 158

14. Db15126

15. Hy-109169

16. Cs-0116355

17. N-((1s)-4-(((1r,2s)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1h-1,2,3-triazol-1-yl)benzamide

18. N-((s)-5-((1r,2s)-2-(4- Fluorophenyl)cyclopropylamino)-1-(4- Methylpiperazin-1-yl)-1-oxopentan-2-yl)-4- (1h-1,2,3-triazol-1-yl)benzamide

19. N-[(2s)-1-(4-(methyl)piperazin-1-yl)-5-[[(1r,2s)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1h-1,2,3-triazol-1-yl)benzamide

2.4 Create Date

2016-12-08

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₃₄FN₇O₂
Molecular Weight	519.6 g/mol
XLogP3	2.3
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	10
Exact Mass	519.27580151 g/mol
Monoisotopic Mass	519.27580151 g/mol
Topological Polar Surface Area	95.4 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	779
Isotope Atom Count	0
Defined Atom Stereocenter Count	3
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1